Longboard Pharmaceuticals Announces $2.6 Billion Sale to Lundbeck
October 15, 2024
October 15, 2024
PALO ALTO, California, Oct. 15 -- Cooley, a law firm, issued the following news release:
New York - October 14, 2024 - Cooley advised Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, on its $2.6 billion sale to Lundbeck.
Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, offering L . . .
New York - October 14, 2024 - Cooley advised Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, on its $2.6 billion sale to Lundbeck.
Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, offering L . . .